Venus Remedies Ltd
Venus Remedies Ltd (VENUSREM) last traded at ₹1,635, a market capitalisation of ₹2,186 crore, on a P/E of 18.8. Over the past 52 weeks the stock has ranged between ₹424 and ₹2,044. Venus Remedies Ltd last reported results for the quarter ended Jun 2026, with sales of ₹179 crore and net profit of ₹23 crore. Figures are as of 25 Aug 2026 and are not real time.
Venus Remedies Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Venus Remedies Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹179 cr, up 30.7% from ₹137 cr a year earlier. Net profit was ₹23 cr, up 130.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 |
| Expenses | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 |
| Operating profit | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 |
| OPM % | 4.5% | 10% | 15% | 11% | 16% | 21% | 24% | 19% |
| Other income | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 |
| Profit before tax | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 |
| Tax % | 61% | 21% | 32% | 24% | 24% | 24% | 23% | 24% |
| Net profit | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 |
| EPS (₹) | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.54 | 17.18 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Venus Remedies Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 544 | 597 | 552 | 596 | 640 | 770 | 811 |
| Operating profit | 54 | 62 | 60 | 60 | 64 | 147 | 166 |
| OPM % | 10% | 10% | 11% | 10% | 10% | 19% | 20% |
| Net profit | 62 | 41 | 27 | 28 | 45 | 103 | 116 |
| EPS (₹) | 50.05 | 30.46 | 19.88 | 21.31 | 33.90 | 76.90 | 86.92 |
TTM is the trailing twelve months to the most recent quarter.
Venus Remedies Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 7%
- 3 Years
- 12%
- TTM
- 20%
- 10 Years
- 51%
- 5 Years
- 22%
- 3 Years
- 57%
- TTM
- 149%
- 10 Years
- 34%
- 5 Years
- 29%
- 3 Years
- 93%
- 1 Year
- 243%
- 10 Years
- 5%
- 5 Years
- 10%
- 3 Years
- 10%
- Last Year
- 17%
Venus Remedies Ltd shareholding pattern
Promoters held 41.76% at Jun 2026, broadly unchanged since Jun 2025. FIIs 2.92% and DIIs 0.89%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| FIIs | 1.18% | 1.11% | 1.34% | 2.25% | 1.86% | 2.25% | 2.80% | 2.92% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.11% | 0.75% | 1.03% | 1.20% | 0.89% |
| Public | 57.06% | 57.13% | 56.90% | 55.89% | 55.62% | 54.95% | 54.24% | 54.44% |
| No. of shareholders | 19,557 | 19,771 | 19,982 | 19,307 | 17,725 | 18,606 | 18,403 | 21,905 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Venus Remedies Ltd corporate filings
- Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAGM/EGMlow impact
Cruxal's analysis: Venus Remedies Limited has successfully concluded its 37th Annual General Meeting held on…
Read the full analysis - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationCompany Updatelow impact
Cruxal's analysis: Venus Remedies Ltd has filed an announcement regarding amendments to its Memorandum and…
Read the full analysis - Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportAGM/EGMlow impact
Cruxal's analysis: Venus Remedies Limited has successfully concluded its 37th Annual General Meeting held on…
Read the full analysis - Announcement under Regulation 30 (LODR)-Change in ManagementCompany Updatelow impact
Cruxal's analysis: Venus Remedies Limited has formalized the appointment and re-appointment of key…
Read the full analysis - Shareholder Meeting / Postal Ballot-Outcome of AGMAGM/EGMlow impact
Cruxal's analysis: Venus Remedies Limited has successfully concluded its 37th Annual General Meeting, where…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Venus Remedies Ltd has made a routine announcement on 2026-08-04 regarding a newspaper…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Venus Remedies Ltd
Cruxal reads every Venus Remedies Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.